Anela Puljic1, Elissa Kim2, Jessica Page3, Tania Esakoff4, Brian Shaffer5, Daphne Y LaCoursiere2, Aaron B Caughey5. 1. Department of Reproductive Medicine, University of California, San Diego, School of Medicine, San Diego, CA. Electronic address: apuljic@ucsd.edu. 2. Department of Reproductive Medicine, University of California, San Diego, School of Medicine, San Diego, CA. 3. Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT. 4. Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA. 5. Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.
Abstract
OBJECTIVE: The objective of the study was to characterize the risk of infant and fetal death by each additional week of expectant management vs immediate delivery in pregnancies complicated by cholestasis. STUDY DESIGN: This was a retrospective cohort study of 1,604,386 singleton, nonanomalous pregnancies of women between 34 and 40 weeks' gestation with and without intrahepatic cholestasis of pregnancy (ICP) in the state of California during the years of 2005-2008. International Classification of Diseases, 9th version, codes and linked hospital discharge and vital statistics data were utilized. For each week of gestation, the following outcomes were assessed: the risk of stillbirth, the risk of delivery (represented by the risk of infant death at a given week of gestation), and the composite risk of expectant management for 1 additional week. Composite risk combines the risk of stillbirth at this gestational age week plus the risk of infant death if delivered at the subsequent week of gestation. RESULTS: Among women with ICP, the mortality risk of delivery is lower than the risk of expectant management at 36 weeks' gestation (4.7 vs 19.2 per 10,000). The risk of expectant management remains higher than delivery and continues to rise by week of gestation beyond 36 weeks. The risk of expectant management in women with ICP reaches a nadir at 35 weeks (9.1 per 10,000; 95% confidence interval, 1.4-16.9) and rises at 36 weeks (19.2 per 10,000; 95% confidence interval, 7.6-30.8). CONCLUSION: Among women with ICP, delivery at 36 weeks' gestation would reduce the perinatal mortality risk as compared with expectant management. For later diagnoses, this would also be true at gestational ages beyond 36 weeks. Timing of delivery must take into account both the reduction in stillbirth risk balanced with the morbidities associated with preterm delivery.
OBJECTIVE: The objective of the study was to characterize the risk of infant and fetal death by each additional week of expectant management vs immediate delivery in pregnancies complicated by cholestasis. STUDY DESIGN: This was a retrospective cohort study of 1,604,386 singleton, nonanomalous pregnancies of women between 34 and 40 weeks' gestation with and without intrahepatic cholestasis of pregnancy (ICP) in the state of California during the years of 2005-2008. International Classification of Diseases, 9th version, codes and linked hospital discharge and vital statistics data were utilized. For each week of gestation, the following outcomes were assessed: the risk of stillbirth, the risk of delivery (represented by the risk of infantdeath at a given week of gestation), and the composite risk of expectant management for 1 additional week. Composite risk combines the risk of stillbirth at this gestational age week plus the risk of infantdeath if delivered at the subsequent week of gestation. RESULTS: Among women with ICP, the mortality risk of delivery is lower than the risk of expectant management at 36 weeks' gestation (4.7 vs 19.2 per 10,000). The risk of expectant management remains higher than delivery and continues to rise by week of gestation beyond 36 weeks. The risk of expectant management in women with ICP reaches a nadir at 35 weeks (9.1 per 10,000; 95% confidence interval, 1.4-16.9) and rises at 36 weeks (19.2 per 10,000; 95% confidence interval, 7.6-30.8). CONCLUSION: Among women with ICP, delivery at 36 weeks' gestation would reduce the perinatal mortality risk as compared with expectant management. For later diagnoses, this would also be true at gestational ages beyond 36 weeks. Timing of delivery must take into account both the reduction in stillbirth risk balanced with the morbidities associated with preterm delivery.
Authors: Tetsuya Kawakita; Laura I Parikh; Patrick S Ramsey; Chun-Chih Huang; Alexander Zeymo; Miguel Fernandez; Samuel Smith; Sara N Iqbal Journal: Am J Obstet Gynecol Date: 2015-06-10 Impact factor: 8.661
Authors: Sven Kehl; Irene Hösli; Ulrich Pecks; Philipp Reif; Ralf L Schild; Markus Schmidt; Dagmar Schmitz; Christiane Schwarz; Daniel Surbek; Michael Abou-Dakn Journal: Geburtshilfe Frauenheilkd Date: 2021-08-09 Impact factor: 2.754
Authors: Fergus W Gardiner; Ruth McCuaig; Chris Arthur; Thomas Carins; Adam Morton; Josephine Laurie; Teresa Neeman; Boon Lim; Michael J Peek Journal: Obstet Med Date: 2018-10-25